Acino Absorbs M8 Pharmaceuticals

Published on: 

Acquisition offers 300 new employees and a bigger product portfolio.

Acino, a Swiss pharmaceutical company, revealed that it has entered into an agreement to acquire M8 Pharmaceuticals, a biopharma organization headquartered in Mexico City. Focusing on licensing, marketing, and distributing medicines in Mexico and Brazil, the acquisition supplements Acino’s current Latin American presence, with operations in eight other countries throughout the region.


“This is a transformative deal for Acino, significantly expanding our presence in Latin America and delivering against our overall strategy and stated intention to increase patient’s access to high-quality pharmaceuticals and diversify our footprint in key high-growth markets,” said Andrew Bird, interim CEO, Acino, in a company press release. “We see M8 and Acino as highly complementary offerings, and we are confident that we can use this acquisition as a catalyst to further increase value and accelerate growth for Acino in this key region.”

Reference: Acino significantly expands presence and capabilities in Latin America through acquisition of M8 Pharmaceuticals. Globe Newswire. September 20, 2023. Accessed September 20, 2023.